Merck & Company, Inc. (NYSE:MRK) had its price objective boosted by equities research analysts at UBS AG from $70.00 to $72.00 in a research report issued on Monday, July 31st, 99wallstreet.com reports. The brokerage presently has a “buy” rating on the stock. UBS AG’s target price would suggest a potential upside of 17.09% from the company’s previous close.
A number of other equities analysts have also issued reports on MRK. Zacks Investment Research raised Merck & from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Wednesday, May 10th. J P Morgan Chase & Co raised their price target on Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BMO Capital Markets raised their price target on Merck & from $68.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Finally, Vetr raised Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price target on the stock in a report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $69.58.
Merck & (MRK) traded down 0.57% during mid-day trading on Monday, reaching $61.49. The company’s stock had a trading volume of 8,421,689 shares. Merck & has a one year low of $58.29 and a one year high of $66.80. The stock’s 50 day moving average is $62.91 and its 200 day moving average is $63.83. The firm has a market cap of $167.71 billion, a PE ratio of 33.29 and a beta of 0.80.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the company posted $0.93 earnings per share. On average, analysts anticipate that Merck & will post $3.87 EPS for the current year.
WARNING: “UBS AG Boosts Merck & Company, Inc. (NYSE:MRK) Price Target to $72.00” was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/merck-company-inc-nysemrk-pt-raised-to-72-00-at-ubs-ag-updated-updated.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. WFG Advisors LP boosted its stake in Merck & by 16.9% in the second quarter. WFG Advisors LP now owns 13,478 shares of the company’s stock valued at $864,000 after buying an additional 1,946 shares during the last quarter. Toronto Dominion Bank boosted its stake in Merck & by 22.4% in the second quarter. Toronto Dominion Bank now owns 1,019,846 shares of the company’s stock valued at $65,359,000 after buying an additional 186,774 shares during the last quarter. Afam Capital Inc. boosted its stake in Merck & by 14.5% in the second quarter. Afam Capital Inc. now owns 36,755 shares of the company’s stock valued at $2,356,000 after buying an additional 4,667 shares during the last quarter. Beaton Management Co. Inc. purchased a new stake in Merck & during the second quarter valued at approximately $1,143,000. Finally, Fort Pitt Capital Group LLC boosted its stake in Merck & by 2.5% in the second quarter. Fort Pitt Capital Group LLC now owns 22,061 shares of the company’s stock valued at $1,414,000 after buying an additional 541 shares during the last quarter. Hedge funds and other institutional investors own 73.46% of the company’s stock.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.